Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Average Rating of “Moderate Buy” from Analysts

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has been assigned an average rating of “Moderate Buy” from the twenty-six research firms that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and twenty-one have issued a buy recommendation on the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $315.58.

ALNY has been the subject of several recent analyst reports. Chardan Capital reiterated a “buy” rating and issued a $300.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Friday, March 21st. Stifel Nicolaus lifted their price target on shares of Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the company a “buy” rating in a research report on Monday, March 31st. Redburn Atlantic initiated coverage on Alnylam Pharmaceuticals in a research note on Monday, March 31st. They set a “buy” rating and a $353.00 price target on the stock. JPMorgan Chase & Co. raised Alnylam Pharmaceuticals from a “neutral” rating to an “overweight” rating and raised their price objective for the company from $280.00 to $328.00 in a research note on Monday, March 24th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $320.00 price objective on shares of Alnylam Pharmaceuticals in a report on Wednesday, April 9th.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CMO Pushkal Garg sold 52,592 shares of the stock in a transaction dated Monday, January 27th. The stock was sold at an average price of $285.00, for a total value of $14,988,720.00. Following the transaction, the chief marketing officer now owns 11,989 shares of the company’s stock, valued at approximately $3,416,865. This represents a 81.44 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $251.56, for a total transaction of $362,246.40. Following the completion of the sale, the executive vice president now owns 12,881 shares in the company, valued at $3,240,344.36. This represents a 10.06 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 71,234 shares of company stock worth $19,958,097. Company insiders own 1.50% of the company’s stock.

Institutional Trading of Alnylam Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the company. Pallas Capital Advisors LLC grew its stake in shares of Alnylam Pharmaceuticals by 94.7% during the 1st quarter. Pallas Capital Advisors LLC now owns 6,635 shares of the biopharmaceutical company’s stock worth $1,792,000 after acquiring an additional 3,227 shares in the last quarter. Wedmont Private Capital boosted its holdings in Alnylam Pharmaceuticals by 7.2% during the first quarter. Wedmont Private Capital now owns 1,592 shares of the biopharmaceutical company’s stock worth $430,000 after purchasing an additional 107 shares during the last quarter. TB Alternative Assets Ltd. bought a new position in Alnylam Pharmaceuticals in the first quarter valued at $2,476,000. Whipplewood Advisors LLC increased its stake in Alnylam Pharmaceuticals by 208.8% in the 1st quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 71 shares during the last quarter. Finally, Merit Financial Group LLC lifted its position in Alnylam Pharmaceuticals by 113.0% during the 1st quarter. Merit Financial Group LLC now owns 5,314 shares of the biopharmaceutical company’s stock worth $1,435,000 after buying an additional 2,819 shares in the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY opened at $240.01 on Tuesday. The company’s 50 day simple moving average is $252.47 and its 200-day simple moving average is $258.02. Alnylam Pharmaceuticals has a 12-month low of $141.98 and a 12-month high of $304.39. The firm has a market cap of $31.22 billion, a PE ratio of -110.60 and a beta of 0.30. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). As a group, equities analysts predict that Alnylam Pharmaceuticals will post -1.7 EPS for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.